References
Primary graft failure is rarely observed after autologous haematopoietic stem cell transplantation, and is usually associated with a high mortality despite infusion of back up graft and administration of haematopoietic growth factors.
Mesenchymal stem cells (MSC) are part of the bone marrow microenvironment and support haematopoiesis. In vitro, MSC can differentiate into several tissues 1 and possess immunosuppressive properties. 2 After intravenous infusion in mice, MSC are detected in a wide range of tissues, including bone marrow, 3 and can enhance engraftment of haematopoietic stem cells. 4 In human, MSC are still investigational and have been used mainly in haematopoietic stem cell transplantation. Indeed, coinfusion of autologous MSC with autologous peripheral blood haematopoietic stem cells in cancer patients receiving high dose chemotherapy resulted in acceleration of haematopoietic recovery 5 and coinfusion of allogeneic haematopoietic stem cells with allogeneic MSC was safe. 6 More importantly, allogeneic MSC could treat successfully steroid resistant acute graft-versus-host disease (GVHD). 7 The place of MSC in the treatment of bone marrow failure is unknown but some in vitro and animal data are in favour to a possible therapeutic role. Indeed, we have previously shown that MSC could improve bone marrow microenvironment in a patient with an end-stage severe aplastic anaemia. 8 We now report on a second patient with bone marrow failure secondary to incomplete engraftment after autologous haematopoietic stem cell transplantation. This patient received infusion of allogeneic MSC. Haematopoiesis recovery was observed with a parallel improvement of in vitro clonogenic assay and detection of allogeneic MSC in recipient bone marrow.
A 40-year-old nulliparous woman with acute myeloid leukaemia received an autologous bone marrow transplantation (ABMT) in complete remission. Conditioning regimen combined a 12 Gray fractionated total body irradiation and high dose cyclophosphamide (120 mg/kg) followed by infusion of marrow purged by mafosfamide. Primary graft failure occurred despite infusion of back up marrow. Partial recovery on polymorphonuclear (PMN) and haemoglobin (Hb) was obtained with granulocyte-colony stimulating factor (G-CSF) and erythropoietin (EPO) administered three times a week. Thrombocytopenia remained permanently below 50 Â 10 9 /l. In order to improve haematopoiesis, infusion of MSC was decided and performed 3 years after ABMT. MSC were isolated from a human leucocyte antigen mismatched brother bone marrow. Under a compassionate use Osiris Therapeutics (Baltimore, MD, USA) manufactured a patient-specific product of ex vivo cultured adult human MSC. Fifty-six millilitre of bone marrow aspirate was obtained under sterile conditions. The culture and expansion of the cells was performed using 10-stack cell factories (Nalge-Nunc, Rochester, NY, USA) and a modification of previously published methods. 9 At the end of the culture/expansion period, cells were harvested, washed, cryopreserved in Plasmalyte-A, 10% dimethylsulphoxide and 5% human serum albumin and stored in the vapour phase of a liquid nitrogen freezer. The final product was tested for sterility, endotoxin, mycoplasma, viability, cell count and phenotype. Allogeneic MSC were infused at a dose of 2.78 Â 10 6 /kg. The procedure was carried out according to the French regulation: French agency AFSSAPS approval, local ethical committee approval and patient signed inform consent were obtained previously. At the time of MSC infusion, the marrow aspirate was hypocellular with no detectable leukaemic blast cells. The baseline blood cell counts was: PMN: 0.8 Â 10 9 /l, platelets: 45 Â 10 9 /l and Hb: 10.5 g/dl. No conditioning regimen and no prophylaxis for GVHD was given. Growth factors were discontinued.
After MSC infusion, a rapid and sustained haematopoietic recovery was observed on both PMN and platelets (Figure 1a and b). There was no effect on Hb recovery. EPO but not GCSF was reintroduced 1 year after MSC infusion. With a follow-up of 24 months, the patient is alive and well. There was no side effect secondary to MSC infusion.
We observed no GVHD, no infection and no secondary malignancy or stromal tumour on CT scan performed 1 year after MSC infusion. Sequential bone marrow biopsies showed no induced myelofibrosis. No leukaemia relapse occurred.
Haematopoietic recovery on PMN and platelets was corroborated by a parallel improvement of in vitro haematopoietic and stromal clonogenic assays. The number of granulomacrophage colony-forming unit (CFU-GM) and CFU-fibroblasts (CFU-F) studied the day before MSC infusion, 1 month and 1 year after MSC infusion, increased significantly (Po0.05) (Figure 2a and b) . Long term culture-initiating cells (LTC-IC) frequency increased significantly 1 year after MSC infusion compared to frequency observed before MSC infusion (Figure 2b ). There was no significant change in BFUE.
We studied engraftment of MSC in recipient bone marrow. DNA extracted from the bone marrow biopsy (ground bone plus marrow) was analysed for mesenchymal chimerism as in previous patient, 8 before infusion of MSC, 1 month and 1 year post-MSC infusion by real-time quantitative polymerase chain reaction (PCR) of the Y-specific SRY gene. Male DNA was not detected before infusion; whereas 1 month post-MSC infusion, male DNA was detected at a frequency of 10 À5 per cell but was not more detectable 1 year after. No male DNA was detected on CFU-F grown from bone marrow after MSC infusion. Previous male DNA contamination in the recipient bone marrow was ruled out, as male DNA had not been detected in the recipient bone marrow before MSC infusion and more importantly, the patient was nulliparous, which definitively eliminates any transplacental microchimerism from a male child pregnancy. This observation confirms previous reports in animals 1 and in human including our own 8 showing that MSC engraft at very low levels in the endosteum (Figure 3) . This observation shows that MSC can induce haematopoietic tissue recovery on PMN and platelets and may have potential for the treatment of bone marrow failure. We previously showed in a first patient that MSC could improve the recipient micro- Haematopoietic recovery on PMN (a) and platelets (b) after MSC infusion for engraftment failure. Haematopoietic and stromal clonogenic assays before and after mesenchymal stem cell infusion. CFU-GM and BFU-E per millilitre of bone marrow aspirate are showed on (a). LTC-IC and CFU-F are showed on (b). Statistical significance was calculated using a t-test performed with the Sigma Stats Software. Significance for all analysis was set at Po0.05. All values are expressed as the mean and s.e.m. (standard error of the mean). Significance for all analysis compared to day À1 before infusion was set at n Po0.05, nn Po0.01, nnn Po0.001 and nonsignificance was noted by NS.
Letters to the Editor environment. 8 In this second observation, we observed that haematopoietic recovery on PMN and platelets could be restored after MSC infusion in the absence of additional haematopoietic stem cell support. Whether this is due to stimulation of residual haematopoietic progenitor stem cells or to another mechanism is not understood yet. The absence of effect on the erythroid lineage is possibly linked to the lack of specific erythropoietic growth factor produced by MSC.
We think that MSC could be considered in the treatment strategy of engraftment failure as well as other bone marrow failure, including severe idiopathic aplastic anaemia and accidental irradiation. Pilot prospective studies are needed to confirm these hypotheses. Cycle number Figure 3 Chimerism analysis of bone marrow biopsy specimens. All experiments were performed in duplicate. Samples I, II were obtained before MSC infusion, samples III, IV, and samples V, VI were obtained 1 month and 1 year post-MSC infusion, respectively. DNA was extracted by phenol chloroform treatment from the whole bone marrow specimens. The SRY gene was amplified together with the F8 reference gene by realtime quantitative PCR. The analysis comprises serial dilution of the tested genes and allowed for quantification of the positive results. SRY-positive DNA (2 pg) was found in 100 ng of total DNA in the 1 month post-infusion sample (1/50 000), whereas the other samples were negative.
